About   Subscribe   Submit   My BJ   Librarians   Authors   Help
Editorial Board
Chair
PR Shepherd - Auckland

Vice Chair, The Americas
G Salvesen - La Jolla, CA

Vice Chair, Asia-Pacific
T Xu - Beijing

Vice Chair, Europe
DR Alessi - Dundee

Vice Chair, Reviews
A Toker - Boston, MA

Deputy Chairs
M Blatt - Glasgow
L Goodyear - Boston, MA
SV Graham - Glasgow
D Hoekstra - Groningen
S Huber - Urbana, IL
J Ladbury - Houston, TX
M Lemmon - Philadelphia, PA
C MacKintosh - Dundee
KH Mayo - Minneapolis, MN
M Murphy - Cambridge
S Roberts - Buffalo, NY
M Schwartz - Charlottesville, VA
D Tosh - Bath
HM Wallace - Aberdeen
Biochem. J. (2000) 350 (429–441) (Printed in Great Britain)
Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes
Stuart M. PITSON, Richard J. D'ANDREA, Lucianne VANDELEUR, Paul A. B. MORETTI, Pu XIA, Jennifer R. GAMBLE, Mathew A. VADAS and Binks W. WATTENBERG1
Hanson Centre for Cancer Research, Division of Human Immunology, Institute of Medical and Veterinary Science, Frome Road, Adelaide 5000, SA, Australia

Sphingosine 1-phosphate (S1P) is a novel lipid messenger that has important roles in a wide variety of mammalian cellular processes including growth, differentiation and death. Basal levels of S1P in mammalian cells are generally low, but can increase rapidly and transiently when cells are exposed to mitogenic agents and other stimuli. This increase is largely due to increased activity of sphingosine kinase (SK), the enzyme that catalyses its formation. In the current study we have purified, cloned and characterized the first human SK to obtain a better understanding of its biochemical activity and possible activation mechanisms. The enzyme was purified to homogeneity from human placenta using ammonium sulphate precipitation, anion-exchange chromatography, calmodulin-affinity chromatography and gel-filtration chromatography. This resulted in a purification of over 106-fold from the original placenta extract. The enzyme was cloned and expressed in active form in both HEK-293T cells and Escherichia coli, and the recombinant E. coli-derived SK purified to homogeneity. To establish whether post-translational modifications lead to activation of human SK activity we characterized both the purified placental enzyme and the purified recombinant SK produced in E. coli, where such modifications would not occur. The premise for this study was that post-translational modifications are likely to cause conformational changes in the structure of SK, which may result in detectable changes in the physico-chemical or catalytic properties of the enzyme. Thus the enzymes were characterized with respect to substrate specificity and kinetics, inhibition kinetics and various other physico-chemical properties. In all cases, both the native and recombinant SKs displayed remarkably similar properties, indicating that post-translational modifications are not required for basal activity of human SK.


Abbreviations used: SK, sphingosine kinase; hSK, human SK; S1P, sphingosine 1-phosphate; TNFa, tumour necrosis factor a; HUVEC, human umbilical vein endothelial cell; IPTG, isopropyl b-D-thiogalactoside; GST, glutathione S-transferase; PKC, protein kinase C; DGK, diacylglycerol kinase; EST, expressed sequence tag.

1 To whom correspondence should be addressed (e-mail brian.wattenberg@imvs.sa.gov.au).

The nucleotide sequence data reported will appear in the GenBank® Nucleotide Sequence Database under accession number AF200328.

Key words: enzyme activation, lipid kinase, second messenger, sphingosine 1-phosphate.

Received 1 March 2000/22 May 2000; accepted 27 June 2000


The Biochemical Society, London © 2000

Chinese users - get faster access here
 
 
 
Make it personal - with My BJ!
Bookmark with:
Bookmark with Del.icio.us Bookmark with Connotea